Type I-F CRISPR-Cas resistance against virulent phages results in abortive infection and provides population-level immunity
dc.contributor.author | Watson, BNJ | |
dc.contributor.author | Vercoe, RB | |
dc.contributor.author | Salmond, GPC | |
dc.contributor.author | Westra, ER | |
dc.contributor.author | Staals, RHJ | |
dc.contributor.author | Fineran, PC | |
dc.date.accessioned | 2020-01-13T15:04:41Z | |
dc.date.issued | 2019-12-04 | |
dc.description.abstract | Type I CRISPR-Cas systems are abundant and widespread adaptive immune systems in bacteria and can greatly enhance bacterial survival in the face of phage infection. Upon phage infection, some CRISPR-Cas immune responses result in bacterial dormancy or slowed growth, which suggests the outcomes for infected cells may vary between systems. Here we demonstrate that type I CRISPR immunity of Pectobacterium atrosepticum leads to suppression of two unrelated virulent phages, ɸTE and ɸM1. Immunity results in an abortive infection response, where infected cells do not survive, but viral propagation is severely decreased, resulting in population protection due to the reduced phage epidemic. Our findings challenge the view of CRISPR-Cas as a system that protects the individual cell and supports growing evidence of abortive infection by some types of CRISPR-Cas systems. | en_GB |
dc.identifier.citation | Vol. 10, article number 5526 | en_GB |
dc.identifier.doi | 10.1038/s41467-019-13445-2 | |
dc.identifier.uri | http://hdl.handle.net/10871/40397 | |
dc.language.iso | en | en_GB |
dc.publisher | Nature Research | en_GB |
dc.rights | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. | en_GB |
dc.title | Type I-F CRISPR-Cas resistance against virulent phages results in abortive infection and provides population-level immunity | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2020-01-13T15:04:41Z | |
dc.identifier.issn | 2041-1723 | |
dc.description | This is the final version. Available from the publisher via the DOI in this record. | en_GB |
dc.identifier.journal | Nature Communications | en_GB |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_GB |
dcterms.dateAccepted | 2019-10-30 | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2019-12-04 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2020-01-13T15:00:41Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2020-01-13T15:04:49Z | |
refterms.panel | A | en_GB |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.